Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $184.00

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target hoisted by Citigroup from $160.00 to $184.00 in a research note released on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other research analysts have also recently issued reports about the company. Morgan Stanley set a $144.00 price target on Mirum Pharmaceuticals in a research report on Monday, September 28th. CLSA set a $146.00 price objective on Mirum Pharmaceuticals in a research report on Monday, June 15th. Weiss Ratings upgraded Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research report on Thursday, August 6th. Wall Street Zen cut shares of Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, September 6th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $147.88.

Mirum Pharmaceuticals Trading Up 0.4%

NASDAQ MIRM opened at $79.96 on Monday. The stock has a 50-day simple moving average of $93.70 and a two-hundred day simple moving average of $100.82. Mirum Pharmaceuticals has a fifty-two week low of $63.23 and a fifty-two week high of $130.00. The company has a current ratio of 2.86, a quick ratio of 2.74 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The company had revenue of $176.24 million during the quarter, compared to analyst estimates of $166.33 million. During the same period last year, the firm earned ($0.12) EPS. The business’s quarterly revenue was up 37.9% compared to the same quarter last year. As a group, equities research analysts forecast that Mirum Pharmaceuticals will post -1.31 earnings per share for the current year.

Insider Activity

In related news, SVP Jolanda Howe sold 658 shares of Mirum Pharmaceuticals stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $100.00, for a total value of $65,800.00. Following the completion of the transaction, the senior vice president owned 616 shares in the company, valued at $61,600. The trade was a 51.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of Mirum Pharmaceuticals stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $98.68, for a total value of $2,960,400.00. Following the completion of the transaction, the chief executive officer owned 194,440 shares of the company’s stock, valued at approximately $19,187,339.20. This represents a 13.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 98,499 shares of company stock worth $9,797,834 in the last ninety days. Company insiders own 8.32% of the company’s stock.

Institutional Trading of Mirum Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Integrated Wealth Concepts LLC purchased a new position in shares of Mirum Pharmaceuticals during the 2nd quarter valued at approximately $27,000. Summit Securities Group LLC acquired a new stake in Mirum Pharmaceuticals in the 1st quarter valued at $42,000. Quantbot Technologies LP purchased a new stake in Mirum Pharmaceuticals in the 2nd quarter worth $44,000. State of Wyoming purchased a new stake in Mirum Pharmaceuticals in the 2nd quarter worth $52,000. Finally, Fifth Third Bancorp purchased a new stake in Mirum Pharmaceuticals in the 1st quarter worth $56,000.

Mirum Pharmaceuticals News Roundup

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Mirum’s Livmarli achieved the primary goal of the Phase III EXPAND study in ultra-rare liver diseases, improving cholestatic itching and reducing serum bile acids. The company plans to submit the data to the FDA in 2027, potentially expanding Livmarli’s addressable market. Mirum’s Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases
• Positive Sentiment: Citigroup reportedly sees substantial upside potential for MIRM, reinforcing the longer-term investment case. Citigroup Forecasts Strong Price Appreciation for Mirum Pharmaceuticals
• Neutral Sentiment: HC Wainwright maintained its Buy rating and $200 price target, well above the stock’s recent trading level. However, the firm lowered its FY2027 EPS forecast to $1.16 from $1.42 and reduced estimates for Q3 2026, Q1 2027, Q2 2027 and Q4 2027. The changes suggest continued confidence in Mirum’s long-term opportunity but a more cautious view of near-term earnings.
• Negative Sentiment: The repeated earnings-estimate cuts could weigh on the stock because they reduce projected profitability and may signal slower-than-expected commercialization, expenses, or revenue growth. Investors may focus on whether Mirum can convert Livmarli’s clinical progress into stronger financial results.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for rare diseases of the liver and gastrointestinal system. The company’s work centers on conditions involving impaired bile acid transport and cholestasis, which can cause serious liver damage and debilitating symptoms such as itching.

Mirum’s primary commercial product is Livmarli (maralixibat), an oral ileal bile acid transporter inhibitor. In the United States, Livmarli is approved to treat cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible pediatric patients.